



 ferrer

Ferrer Who we are

International privately-held pharmaceutical company

Founded in 1959

Business areas

Pharmaceuticals

OTCs & personal health

Diagnostics

Fine chemicals

Food & feed additives

Mission

To advance the wellbeing of society

Worldwide operations

Headquarter in Barcelona

Presence in 93 countries


Ferrer Turnover & Staff

Total turnover 2014 €795 million

International turnover €427 million (54% of total)

Total staff 2014 1,991 (Abroad 370)

Ferrer Global sales



Ferrer as Core Partner

EIT Health Challenges

To promote healthy living

- ❑ Self-management of Health
- ❑ **Life Style Intervention**

To support active ageing

- ❑ Workplace interventions
- ❑ Overcoming functional loss

To improve healthcare

- ❑ **Chronic disease treatment & management**
- ❑ **Improving healthcare systems**

EIT Health & Ferrer Objectives

Objectives

Early detection & Prevention

Therapy Disease Management






Improving healthcare system and sustainability

Cost-efficient integrated healthcare solutions

Growth through increased Global
Commercialization and Competitiveness


Models for Health Management

Ferrer as Core Partner









| | TRL5 | TRL6 | TRL9 | KIC Partners |
|-----------------------------------|------|------|------|---|
| Cancer Management | | | |   |
| Cardiovascular Disease Management | | | |   |
| Healthy Brain | | | |  |

Technology Readiness Level
TRL5 Large Scale Prototype
TRL6 Prototype System
TRL9 Full commercial application


Ferrer Platform



Ferrer Diagnostics

| Diagnostic | Objective | Status |
|--|---|---|
|  | Epigenetic platform to select adequate treatment for poorly managed cancer patients | Development  Advanced Biotherapeutics |
|  | Risk of suffering a cardiovascular event in the next 10 years | Marketed  |
|  | Risk of suffering a thromboembolic event | Marketed  |
|  | Predisposition to obesity and response to different therapeutic interventions | Marketed  |

Ferrer Cell Therapy



histocell
©HistoCell

NeuroSave


ferrer

Advanced
Biotherapeutics

Traumatic Spinal Cord Injury is a **devastating** condition for which there is **as yet no cure**. It affects **2.5 million people** and generates the highest social cost and burden due to high dependence during a long period of life

Use of a **patented** specially conditioned **adipose-derived mesenchymal cells**. Such cells are **able to survive** in an **extremely oxidative and inflammatory** environment as the one present in the spinal lesion.

Ferrer Drug Therapy



Public Health Intervention in Cardiovascular Prevention




Patient
Convenience

Improved
Adherence

Reduction of CV

Reduction of
associated
costs

Ferrer Drug Therapy





Making
people
better